Related Experiment Videos
A ten year follow-up after immunization with a two component acellular pertussis vaccine
Y Tindberg1, M Blennow, M Granström
1Department of Pediatrics, Sachs' Children's Hospital, Stockholm, Sweden.
Insights
Long-term immunity to pertussis is maintained ten years after vaccination. Acellular pertussis booster vaccines provide good protection regardless of priming doses.
Area of Science:
- Immunology
- Vaccinology
- Public Health
Background:
- Pertussis (whooping cough) remains a significant public health concern.
- Understanding long-term immunity after different vaccination schedules is crucial for effective disease control.
Purpose of the Study:
- To evaluate the duration of antitoxin response and immunity to pertussis.
- To compare immune responses 10 years post-priming with acellular or whole-cell pertussis vaccines followed by an acellular booster.
Main Methods:
- A cohort study involving 207 children at 11 years of age.
- Analysis of neutralizing antibodies to pertussis toxin using the Chinese hamster ovary cell assay.
- Assessment of clinical pertussis and exposure via a structured questionnaire.
Main Results:
- Measurable antitoxin antibodies were present in 77% of participants.
- No significant difference in antibody levels based on vaccine type or priming doses.
- A decrease in antibody concentration was observed from age 4, with spontaneous titer rises in 14% of children.
- Clinical pertussis was confirmed in 5% of children during follow-up.
Conclusions:
- Antitoxin concentrations are maintained during endemic pertussis.
- Acellular pertussis boosters provide good long-term protection.
- Immunity duration is independent of the priming vaccine type or number of acellular doses.
Objectives:
To investigate the duration of antitoxin response and immunity to pertussis 10 years after priming with either two or three doses of a two component acellular pertussis vaccine or with three doses of a whole cell vaccine and then boostered with the acellular vaccine.
Subjects:
At 11 years of age 207 of 304 (68%) children of the original cohort returned for a blood sample and 262 (86%) participated by answering a questionnaire.
Methods:
Neutralizing antibodies to pertussis toxin (antitoxin) were analyzed by the Chinese hamster ovary cell assay. Clinical pertussis and pertussis exposure were investigated by a structured questionnaire.
Results:
Measurable antitoxin was found in 77% of the samples, with no differences by type of vaccine or by the number of doses given for priming. A significant decrease of antibody concentration (P<0.001) was noted from the previous recall at 4 years of age, and significant titer rises were found for 14% of the children, irrespective of known exposure. Confirmed pertussis during follow-up, as defined in the study, was reported for 14 of 262 (5%) children.
Conclusions:
The study showed that antitoxin concentrations are maintained in a situation of endemic pertussis and indicated that the long term protection after an acellular booster was good, irrespective of type of vaccine or the number of doses of acellular vaccine given for priming.